Innovative retatrutide, a dual -action medication targeting both GLP-1 and GIP receptors, is sparking considerable buzz within the weight loss community. Preliminary clinical trials have shown substantial losses in overall weight and advancements in metabolic markers for individuals with excess weight . Scientists believe this unique approach may